InsidersTradesSigma
Total declarations
Companies
▲ Purchases (28 ops.)
▼ Sales (9 ops.)
Insider track record
OtherDisclosed buys
28
Disclosed sells
9
T+90 hit rate
0%
T+90 mean return
-17.4%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Casdin Partners Master Fund, L.P.. Insider active across 6 companies, notably Verve Therapeutics, Inc.. Aggregated, 48 disclosures have been logged. Breakdown: 28 buys · 9 sells. Total volume traded: €149.1m. Activity tracked since 26 July 2021. The latest transaction was disclosed on 19 May 2026 (Cession). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Casdin Partners Master Fund, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations48 total
300,000 shares@ US$22.650.50% mcap15.2% of flowCommon Stock, par value $0.001 per shareSEC:0000919574-26-003646:0
250,000 shares@ US$23.700.44% mcap13.2% of flowCommon Stock, par value $0.001 per shareSEC:0000919574-26-003646:1
650,000 shares@ US$23.701.14% mcap34.4% of flowCommon Stock, par value $0.001 per shareSEC:0000919574-26-003646:2
125,000 shares@ US$1.42010.2% of flowCommon Stock, $0.001 par value per shareSEC:0000919574-25-007243:0
Canonical exit: 2 Mar 2026 (T+90)
150,000 shares@ US$1.43250.2% of flowCommon Stock, $0.001 par value per shareSEC:0000919574-25-007187:0
Canonical exit: 22 Feb 2026 (T+90)
275,000 shares@ US$1.23420.3% of flowCommon Stock, $0.001 par value per shareSEC:0000919574-25-007124:0
Canonical exit: 16 Feb 2026 (T+90)
450,000 shares@ US$1.20310.5% of flowCommon Stock, $0.001 par value per shareSEC:0000919574-25-007087:0
Canonical exit: 11 Feb 2026 (T+90)
225,000 shares@ US$1.12340.2% of flowCommon Stock, $0.001 par value per shareSEC:0000919574-25-006597:0
Canonical exit: 5 Feb 2026 (T+90)
750,000 shares@ US$28.547118.8% of flowCommon Stock, par value $0.001 per shareSEC:0000919574-25-006180:0
100,000 shares@ US$1.28920.1% of flowCommon Stock, $0.001 par value per shareSEC:0000919574-25-005636:0
Canonical exit: 8 Dec 2025 (T+90)
250,000 shares@ US$1.26560.3% of flowCommon Stock, $0.001 par value per shareSEC:0000919574-25-005603:0
Canonical exit: 2 Dec 2025 (T+90)
200,000 shares@ US$1.26340.2% of flowCommon Stock, $0.001 par value per shareSEC:0000919574-25-005152:0
Canonical exit: 20 Nov 2025 (T+90)
500,000 shares@ US$24.4013.2% of flowCommon Stock, par value $0.001 per shareSEC:0000919574-25-005051:0
75,000 shares@ US$1.31040.1% of flowCommon StockSEC:0000919574-25-004979:0
Canonical exit: 11 Nov 2025 (T+90)
500,000 shares@ US$22.6014.1% of flowCommon Stock, par value $0.001 per shareSEC:0000919574-25-004702:0
1,000,000 shares@ US$23.8035.1% of flowCommon Stock, par value $0.001 per shareSEC:0000919574-25-003572:0
27,994 sharesCommon Stock, par value $.001 per shareSEC:0000919574-25-002362:0
4,820,959 shares@ US$1.0655.1% of flowCommon StockSEC:0000919574-25-001777:0
Canonical exit: 29 May 2025 (T+90)
250,000 shares@ US$2.1870.5% of flowCommon StockSEC:0000919574-24-005134:0
Canonical exit: 25 Nov 2024 (T+90)
307,900 shares@ US$1.95780.6% of flowCommon StockSEC:0000919574-24-004878:0
Canonical exit: 20 Nov 2024 (T+90)
250,000 shares@ US$1.85290.4% of flowCommon StockSEC:0000919574-24-004812:0
Canonical exit: 17 Nov 2024 (T+90)
1,200,000 shares@ US$1.59461.8% of flowCommon StockSEC:0000919574-24-004802:0
Canonical exit: 12 Nov 2024 (T+90)
525,408 shares@ US$1.61490.8% of flowCommon StockSEC:0000919574-24-004593:0
Canonical exit: 7 Nov 2024 (T+90)
500,000 shares@ US$1.57240.7% of flowCommon StockSEC:0000919574-24-004339:0
Canonical exit: 5 Nov 2024 (T+90)
200,000 shares@ US$1.58390.3% of flowCommon StockSEC:0000919574-24-004280:1
Canonical exit: 3 Nov 2024 (T+90)
25 of 48 declarations
About Casdin Partners Master Fund, L.P.
Casdin Partners Master Fund, L.P. is a declarant linked to 47 filings, with reported positions in Standard Biotools INC., Biolife Solutions INC, Maxcyte, INC., Tenaya Therapeutics, Inc., Absci Corp and Verve Therapeutics, Inc. In the sampled recent filings from 2021-06-22 to 2026-05-21, the stated buy and sell amounts are 47613151 and 101477114 EUR, and the modal transaction nature is Acquisition.
